Beam Therapeutics Inc
NASDAQ:BEAM 9:50:46 AM EDT
| Market Cap (Intraday) | 1.90B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $24.20 |
| 50-Day MA | $25.78 |
| 200-Day MA | $33.52 |
Beam Therapeutics Inc Stock, NASDAQ:BEAM
238 Main Street, 9th floor, Cambridge, Massachusetts 02142-1016
United States of America
Phone: +1.857.327.8775
Number of Employees: 507
Description
Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.